Abstract
Atypical antipsychotic-induced hyperprolactinemia can cause important clinical symptoms, particularly in young women and also in men, such as impotence, loss of libido, gynecomastia, anovulation and galactorrhea.
Methods: Observational over one-year follow-up of six patients (four women and two men, mean age of 31.1 years, range 26-37), treated with different atypical antipsychotics in an outpatient psychiatric device, who had clinical complications associated to high prolactin serum levels. All of them were treated with standard doses of cabergoline.
Results: Most patients experienced significant clinical improvement after treatment with standard doses of cabergoline (mean dosage 1.08 mg/week), maintained for a mean of 18 month. Normal prolactin levels were achieved after the first months of treatment with cabergoline. No side effects or worsening of psychotic or behavioral symptoms were observed.
Conclusions: Long-term treatment with cabergoline seems to be safe in atypical antipsychotic-treated patients.
Keywords: Atypical antipsychotics, cabergoline, dopamine, hyperprolactinaemia, hypothalamus, pituitary gland, prolactin, schizophrenia.
Current Drug Safety
Title:Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Volume: 7 Issue: 2
Author(s): Ramon Coronas, Jesus Cobo, Olga Gimenez-Palop, Emilio Ortega and Manel Marquez
Affiliation:
Keywords: Atypical antipsychotics, cabergoline, dopamine, hyperprolactinaemia, hypothalamus, pituitary gland, prolactin, schizophrenia.
Abstract: Atypical antipsychotic-induced hyperprolactinemia can cause important clinical symptoms, particularly in young women and also in men, such as impotence, loss of libido, gynecomastia, anovulation and galactorrhea.
Methods: Observational over one-year follow-up of six patients (four women and two men, mean age of 31.1 years, range 26-37), treated with different atypical antipsychotics in an outpatient psychiatric device, who had clinical complications associated to high prolactin serum levels. All of them were treated with standard doses of cabergoline.
Results: Most patients experienced significant clinical improvement after treatment with standard doses of cabergoline (mean dosage 1.08 mg/week), maintained for a mean of 18 month. Normal prolactin levels were achieved after the first months of treatment with cabergoline. No side effects or worsening of psychotic or behavioral symptoms were observed.
Conclusions: Long-term treatment with cabergoline seems to be safe in atypical antipsychotic-treated patients.
Export Options
About this article
Cite this article as:
Coronas Ramon, Cobo Jesus, Gimenez-Palop Olga, Ortega Emilio and Marquez Manel, Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics, Current Drug Safety 2012; 7 (2) . https://dx.doi.org/10.2174/157488612802715753
DOI https://dx.doi.org/10.2174/157488612802715753 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intravitreal Bevacizumab for Diabetic Retinopathy
Current Diabetes Reviews Hydrogen Sulfide: A New Tool to Design and Develop Drugs
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) TNNI3K Could be a Novel Molecular Target for the Treatment of Cardiac Diseases
Recent Patents on Cardiovascular Drug Discovery CD36 as a Multiple-Ligand Signaling Receptor in Atherothrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Multifunctional RNase MCPIP1 and its Role in Cardiovascular Diseases
Current Medicinal Chemistry Antithrombotic / Antiplatelet Therapy in Patients with Stable Coronary Artery Disease and After Acute Coronary Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry A Systematic Review of a Naturally Occurring Iridoid: Catalpol
Current Bioactive Compounds Dapagliflozin Protects H9c2 Cells Against Injury Induced by Lipopolysaccharide via Suppression of CX3CL1/CX3CR1 Axis and NF-κB Activity
Current Molecular Pharmacology Current Status of Rho-Associated Kinases (ROCKs) in Coronary Atherosclerosis and Vasospasm
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Strategies to Ameliorate Radiation Injury: A Possible Role for Tetrahydrobiopterin
Current Drug Targets Neurotrophin-3 Stimulates Migration of Mesenchymal Stem Cells Overexpressing TrkC
Current Medicinal Chemistry Acetaminophen (Paracetamol) and Injury in the Cardiovascular System
Vascular Disease Prevention (Discontinued) Gene Modified Cell Transplantation for Vascular Regeneration
Current Gene Therapy Translational Imaging of Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments
Current Vascular Pharmacology Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry Comparison of Granulomatosis with Polyangiitis Clinical Features in Patients Depending on Involvement or Absence of Kidney Involvement
Current Rheumatology Reviews Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol Derivatives
Mini-Reviews in Medicinal Chemistry Vasomotor Effects of Iodinated Contrast Media: Just Side Effects?
Current Vascular Pharmacology